PMC:7228307 / 25526-25797 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"446","span":{"begin":81,"end":88},"obj":"Gene"},{"id":"447","span":{"begin":111,"end":118},"obj":"Gene"},{"id":"448","span":{"begin":123,"end":128},"obj":"Gene"}],"attributes":[{"id":"A446","pred":"tao:has_database_id","subj":"446","obj":"Gene:2214"},{"id":"A447","pred":"tao:has_database_id","subj":"447","obj":"Gene:2212"},{"id":"A448","pred":"tao:has_database_id","subj":"448","obj":"Gene:2214"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The improvement in clinical utility of mAbs engineered for selectively increased FcγRIII binding suggests that FcγRIIa and FcγRI may be less important in vivo in cell killing effects but perhaps are more important in other aspects of therapeutic efficacy—discussed later."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T255","span":{"begin":162,"end":166},"obj":"Body_part"}],"attributes":[{"id":"A255","pred":"fma_id","subj":"T255","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"The improvement in clinical utility of mAbs engineered for selectively increased FcγRIII binding suggests that FcγRIIa and FcγRI may be less important in vivo in cell killing effects but perhaps are more important in other aspects of therapeutic efficacy—discussed later."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T486","span":{"begin":81,"end":83},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T487","span":{"begin":111,"end":113},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T488","span":{"begin":123,"end":125},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T489","span":{"begin":162,"end":166},"obj":"http://purl.obolibrary.org/obo/GO_0005623"}],"text":"The improvement in clinical utility of mAbs engineered for selectively increased FcγRIII binding suggests that FcγRIIa and FcγRI may be less important in vivo in cell killing effects but perhaps are more important in other aspects of therapeutic efficacy—discussed later."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T132","span":{"begin":126,"end":128},"obj":"Chemical"}],"attributes":[{"id":"A132","pred":"chebi_id","subj":"T132","obj":"http://purl.obolibrary.org/obo/CHEBI_73814"},{"id":"A133","pred":"chebi_id","subj":"T132","obj":"http://purl.obolibrary.org/obo/CHEBI_8753"}],"text":"The improvement in clinical utility of mAbs engineered for selectively increased FcγRIII binding suggests that FcγRIIa and FcγRI may be less important in vivo in cell killing effects but perhaps are more important in other aspects of therapeutic efficacy—discussed later."}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T151","span":{"begin":162,"end":166},"obj":"http://purl.obolibrary.org/obo/CL_0000000"}],"text":"The improvement in clinical utility of mAbs engineered for selectively increased FcγRIII binding suggests that FcγRIIa and FcγRI may be less important in vivo in cell killing effects but perhaps are more important in other aspects of therapeutic efficacy—discussed later."}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"446","span":{"begin":81,"end":88},"obj":"Gene"},{"id":"447","span":{"begin":111,"end":118},"obj":"Gene"},{"id":"448","span":{"begin":123,"end":128},"obj":"Gene"}],"attributes":[{"id":"A446","pred":"pubann:denotes","subj":"446","obj":"Gene:2214"},{"id":"A447","pred":"pubann:denotes","subj":"447","obj":"Gene:2212"},{"id":"A448","pred":"pubann:denotes","subj":"448","obj":"Gene:2214"}],"text":"The improvement in clinical utility of mAbs engineered for selectively increased FcγRIII binding suggests that FcγRIIa and FcγRI may be less important in vivo in cell killing effects but perhaps are more important in other aspects of therapeutic efficacy—discussed later."}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T148","span":{"begin":0,"end":271},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The improvement in clinical utility of mAbs engineered for selectively increased FcγRIII binding suggests that FcγRIIa and FcγRI may be less important in vivo in cell killing effects but perhaps are more important in other aspects of therapeutic efficacy—discussed later."}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T254","span":{"begin":162,"end":166},"obj":"Body_part"}],"attributes":[{"id":"A254","pred":"fma_id","subj":"T254","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"The improvement in clinical utility of mAbs engineered for selectively increased FcγRIII binding suggests that FcγRIIa and FcγRI may be less important in vivo in cell killing effects but perhaps are more important in other aspects of therapeutic efficacy—discussed later."}

{"project":"LitCovid-sample-PD-MAT","denotations":[{"id":"T11","span":{"begin":265,"end":270},"obj":"http://purl.obolibrary.org/obo/MAT_0000488"}],"text":"The improvement in clinical utility of mAbs engineered for selectively increased FcγRIII binding suggests that FcγRIIa and FcγRI may be less important in vivo in cell killing effects but perhaps are more important in other aspects of therapeutic efficacy—discussed later."}

{"project":"LitCovid-sample-PD-GO-BP-0","denotations":[{"id":"T67","span":{"begin":162,"end":174},"obj":"http://purl.obolibrary.org/obo/GO_0001906"}],"text":"The improvement in clinical utility of mAbs engineered for selectively increased FcγRIII binding suggests that FcγRIIa and FcγRI may be less important in vivo in cell killing effects but perhaps are more important in other aspects of therapeutic efficacy—discussed later."}

{"project":"LitCovid-sample-GO-BP","denotations":[{"id":"T67","span":{"begin":162,"end":174},"obj":"http://purl.obolibrary.org/obo/GO_0001906"}],"text":"The improvement in clinical utility of mAbs engineered for selectively increased FcγRIII binding suggests that FcγRIIa and FcγRI may be less important in vivo in cell killing effects but perhaps are more important in other aspects of therapeutic efficacy—discussed later."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T67","span":{"begin":162,"end":174},"obj":"http://purl.obolibrary.org/obo/GO_0001906"}],"text":"The improvement in clinical utility of mAbs engineered for selectively increased FcγRIII binding suggests that FcγRIIa and FcγRI may be less important in vivo in cell killing effects but perhaps are more important in other aspects of therapeutic efficacy—discussed later."}

{"project":"LitCovid-sentences","denotations":[{"id":"T148","span":{"begin":0,"end":271},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The improvement in clinical utility of mAbs engineered for selectively increased FcγRIII binding suggests that FcγRIIa and FcγRI may be less important in vivo in cell killing effects but perhaps are more important in other aspects of therapeutic efficacy—discussed later."}